Potential of mezlocillin as empiric single-agent therapy in febrile granulocytopenic cancer patients.
Mezlocillin was used as an initial empiric antibiotic therapy for febrile (> 101 degrees F, ca. 38.33 degrees C) granulocytopenic (< 1,000/microliter) cancer patients. Patients known to be colonized with an organism resistant to 100 micrograms of mezlocillin per mol were excluded. The initial 25 cas...
Uloženo v:
| Vydáno v: | Antimicrob Agents Chemother |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society for Microbiology (ASM)
1980
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC283987/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/6449902/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.18.2.299 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|